(Q40645833)

22 September 2017

title

Intralesional administration of biological response modifiers in the treatment of localized cancer of the prostate: a feasibility study (English)

1 reference

22 September 2017

A Morales

1

1 reference

22 September 2017

B Johnston

series ordinal

2

1 reference

22 September 2017

L Emerson

series ordinal

3

1 reference

22 September 2017

J W Heaton

series ordinal

4

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

22 September 2017

1 reference

22 September 2017

volume

50

1 reference

22 September 2017

issue

4

1 reference

22 September 2017

page(s)

495-502

1 reference

Impact of Radical Prostatectomy in the Management of Clinically Localized Disease

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Population-based study of long-term survival in patients with clinically localised prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Should cryosurgery be considered a therapeutic option in localized prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Should brachytherapy be considered a therapeutic option in localized prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Long-term control of prostate cancer with radiation. Past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Immunotherapy of prostatic cancer with Bacillus Calmette-Guérin and purified protein derivative. Preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Adjuvant immunotherapy with B.C.G. in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Induction of controlled prostatic tissue necrosis by bacille Calmette-Guérin derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Immunotherapy of an experimental adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

RRR-alpha-tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Chemoimmunoprophylaxis of an experimental bladder cancer with retinoids and Bacillus Calmette Guérin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

Retinoids and interferon: a new promising combination?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900402-0

7 January 2021

10.1016/S0090-4295(97)00402-0

Identifiers

DOI

1 reference

22 September 2017

1 reference